NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Molecular Partners AG MOLN
7 fiscal years on record · CHF · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
CHF -1.65
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 7-year series below
Revenue
Net income
Per share
CHF -1.65
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-47.3%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+38.5%
Change, 10 years—
The share count grew 39% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CHF 102.1M
total assets, end of FY2025
Total assetsCHF 102.1M
CashCHF 82.7M
Current ratio8.79×
History
7 fiscal years
Every figure from documents filed with the SEC · CHF
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue CHF B
0.0
0.0
0.0
0.2
0.0
0.0
0.0
Operating income CHF B
−0.1
−0.1
−0.1
0.1
−0.1
−0.1
−0.0
EBITDA CHF B
·
·
·
·
·
·
·
Income tax CHF B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income CHF B
−0.1
−0.1
−0.1
0.1
−0.1
−0.1
−0.0
EPS, diluted CHF
−1.65
−1.59
−1.89
3.54
−2.06
−2.51
−1.69
Dividend / sh CHF
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
Shares out B
0.04
0.04
0.04
0.04
0.03
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed